Abstract 1647P
Background
Pancreatic cancer is a highly fatal and aggressive disease due to its discouraging mortality and clinical treatment efficacy. Pancreas is composed of endocrine and exocrine parts, and the interlacing structure of them reminds us of the potential interaction between endocrine and exocrine cells in the oncogenesis and development of pancreatic cancer.
Methods
We depicted the changes of pancreatic endocrine cells in pancreatic cancer tissues by single-cell transcriptome sequencing, spatial transcriptome sequencing and multiplexed immunohistochemistry in human as well as in mouse models. After that, the interaction and sequence between pancreatic cancer oncogenesis and endocrine changes was explored in orthotopic transplantation mice and KPC mice. Finally, we proved the mechanism of the interaction between endocrine and exocrine parts of the pancreas through islet isolation, co-culture in vitro and co-injection in vivo.
Results
We found that, compared with normal pancreatic tissue, pancreatic endocrine cells displayed significantly different transcriptomic characteristics and increased interaction with exocrine part in pancreatic cancer tissues. Specifically, pancreatic polypeptide positive (PP+) cells showed a sharp increment accompanied with the progression of the cancer lesion. From an evolutionary perspective, the increased PP+ cells might be derived from the trans differentiation of α and β cells. Interestingly, in vivo and in vitro experiments proved that pancreatic cancer cells were able to induce the trans differentiation of α cells and β cells into GCG+PP+ and INS+PP+ double-positive cells, which further promoted pancreatic cancer proliferation in a paracrine-dependent manner and formed a positive feedback loop.
Conclusions
Our study systematically mapped the changes of pancreatic endocrine cells in pancreatic cancer and elucidated their relationship with pancreatic cancer oncogenesis and development. Meanwhile, we first time defined and characterized cancer-associated endocrine cells (CAE), which indicated that pancreatic endocrine cells should be an important component of pancreatic cancer microenvironment, thereby providing novel ideas for early diagnosis and targeted therapy of pancreatic cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
National Nature Science Foundation of China, Chinese Academy of Medical Sciences, Peking Union Medical College Hospital, China Postdoctoral Science Foundation.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1634P - Extensive molecular profiling of KRAS wild-type versus KRAS mutant pancreatic ductal adenocarcinoma on 233 patients
Presenter: Jeanne Lena
Session: Poster session 22
1635P - Germline pathogenic variants of cancer predisposition genes in a multicentre Italian cohort of pancreatic ductal adenocarcinoma patients
Presenter: Giulia Orsi
Session: Poster session 22
1636P - Circulating tumor DNA (ctDNA) profile in patients (pts) with pancreatic cancer (PC): A multicenter experience and challenges for clinical application
Presenter: Francisco Muñoz i Carrillo
Session: Poster session 22
1637P - Early retention of KRAS mutations in cfDNA is an ominous sign for pancreatic cancer patients during chemotherapy: A prospective cohort study
Presenter: Chien-Jui Huang
Session: Poster session 22
1638P - The prognostic and predictive role of class III β-tubulin and hENT1 expression in patients with advanced pancreatic ductal adenocarcinoma
Presenter: Taha Koray Sahin
Session: Poster session 22
1639P - Feasibility of tumor genomic sequencing on tissue obtained from endoscopic ultrasound in patients with pancreatic cancer
Presenter: Vaia Florou
Session: Poster session 22
1640P - Response monitoring with ctDNA in metastatic pancreatic cancer
Presenter: Jinwoo Ahn
Session: Poster session 22
1642P - Prognostic impact of an immunomorphological signature integrating immune, fibroblastic and tumor markers in a series of 217 resected pancreatic adenocarcinoma patients
Presenter: Franck MONNIEN
Session: Poster session 22
1643P - Clinical outcomes of FOLFIRINOX as front-line therapy in patients with localized pancreatic adenocarcinoma: Asian retrospective study of 781 patients
Presenter: Kyunghye Bang
Session: Poster session 22